Fehmi Tabak

Fehmi Tabak

Auto-generated profile, based on publicly available information

Fehmi Tabak

Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MSMehmet Soy
Mehmet Soy
GKGökhan Keser
Gökhan Keser
PAPamir Atagündüz
Pamir Atagündüz
FTFehmi Tabak
Fehmi Tabak
IAIsik Atagunduz
Isik Atagunduz
SKServet Kayhan
Servet Kayhan

1 January 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
PMPatrick Marcellin
Patrick Marcellin
SASang Hoon Ahn
Sang Hoon Ahn
XMXiaoli Ma
Xiaoli Ma
FCFlorin A. Caruntu
Florin A. Caruntu
WTWon Young Tak
Won Young Tak
HCHenry L.Y. Chan
Henry L.Y. Chan
Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial. In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus peginterferon for 48 weeks (group A), TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or peginterferon for 48 weeks (group D). The primary end point was the proportion of patients with serum HBsAg loss at week 72. At week seventy-two, 9.1% of subjects in group A had HBsAg loss compared with 2.8% of subjects in group B, none of the subjects in group C, and 2.8% of subjects in group D. A significantly higher proportion of subjects in group A had HBsAg loss than in group C (P < .001) or group D (P = .003). However, the proportions of subjects with HBsAg loss did not differ significantly between group B and group C (P = .466) or group D (P = .883). HBsAg loss in group A occurred in hepatitis B e antigen−positive and hepatitis B e antigen−negative patients with all major viral genotypes. The incidence of common adverse events (including headache, alopecia, and pyrexia) and treatment discontinuation due to adverse events was similar among groups. A significantly greater proportion of patients receiving TDF plus peginterferon for 48 weeks had HBsAg loss than those receiving TDF or peginterferon alone. ClinicalTrials.gov ID NCT01277601.

27 April 2016 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
ROResat Ozaras
Resat Ozaras
HLHakan Leblebicioglu
Hakan Leblebicioglu
MSMustafa Sunbul
Mustafa Sunbul
FTFehmi Tabak
Fehmi Tabak
IBIlker Inanc Balkan
Ilker Inanc Balkan
RORecep Ozturk
Recep Ozturk
The conflict in Syria is a big humanitarian emergency. More than 200,000 Syrians have been killed, with more than half of the population either having been displaced or having immigrated. Healthcare has been interrupted due to the destruction of facilities, a lack of medical staff, and a critical shortage of life-saving medications. It produced suitable conditions leading to the re-emergence of tuberculosis, cutaneous leishmaniasis, polio, and measles. Lebanon and Jordan reported increased rates of tuberculosis among Syrian refugees. Cutaneous leishmaniasis outbreaks were noted not only in Syria but also in Turkey, Jordan, and Lebanon. After a polio-free 15 years, Syria reported a polio outbreak. Ongoing measles outbreaks in the region was accelerated by the conflict. Iraq declared a cholera outbreak among the Syrian refugees. The healthcare facilities of the countries hosting immigrants, mainly Turkey, Lebanon, Jordan, Iraq, and Egypt, are overburdened. The majority of the immigrants live in crowded and unsanitary conditions. Infectious diseases are big challenges for Syria and for the countries hosting immigrants. More structured support from international organizations is needed for the prevention, control, diagnosis, and treatment of infectious diseases.

29 March 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
BYBerna Yurttas
Berna Yurttas
BPBurc Cagri Poyraz
Burc Cagri Poyraz
NSNecdet Sut
Necdet Sut
AOAyse Ozdede
Ayse Ozdede
MOMert Oztas
Mert Oztas
ESEmire Seyahi
Emire Seyahi
Objectives Vaccination against COVID-19 emerges as an effective strategy for combating the pandemic. While many of our patients with rheumatic diseases (RD) wonder whether it is safe to get the vaccine, vaccine hesitancy is rising among the general population. We assessed the willingness to get vaccination and its probable predictors among patients with RD compared to healthcare workers and a sample from the general population. Methods We conducted a web-based questionnaire survey in a cross-sectional design in 3 groups of participants just before the mass vaccination program in Istanbul, Turkey. The questionnaire sought socio-demographic variables, COVID-19 related risk factors, willingness to get vaccination, and concerns and thoughts about vaccine. COVID-19 anxiety scale (CAS) was also evaluated. Results We studied in total 732 patients with RD (Group 1), 763 individuals representing general population (Group 2) and 320 hospital workers (Group 3). Dysfunctional anxiety related to COVID-19 was found in 4.9%, 3.8% and 4.1%, in Group 1, 2 and 3, respectively. Of the patients with RD, 29.2% were willing to be vaccinated, 19.0% were unwilling and 51.8% were undecided. These were somewhat similar among the general population (yes: 34.6%, no: 23.3% and unsure: 42.1%), with significantly less undecided individuals (p < 0.001). On the other hand, hospital workers were significantly more willing (yes: 52.5%, no: 20.9% and unsure: 26.6%) (p < 0.001). Main concerns were probable side effects, unknown scientific results and having no trust. Being male, older age, working in a hospital, not having contracted COVID-19 and high scores on CAS were found to be independently associated with willingness. Conclusions The low rate of vaccine acceptance among patients with RD, as well as general population sampling is worrying. Healthcare policies should aim to implement communication, promote confidence and increase demand for COVID-19 vaccine.

9 June 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ESEmire Seyahi
Emire Seyahi
GBGuldaran Bakhdiyarli
Guldaran Bakhdiyarli
MOMert Oztas
Mert Oztas
MKMert Ahmet Kuskucu
Mert Ahmet Kuskucu
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
VHVedat Hamuryudan
Vedat Hamuryudan

22 August 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
SASang Hoon Ahn
Sang Hoon Ahn
PMPatrick Marcellin
Patrick Marcellin
XMXiaoli Ma
Xiaoli Ma
FCFlorin A. Caruntu
Florin A. Caruntu
WTWon Young Tak
Won Young Tak
HCHenry L. Y. Chan
Henry L. Y. Chan
Background and Aims Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120. Methods In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed. Results Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P < 0.001 for both) or group D (HBsAg loss: P = 0.002; HBsAg seroconversion: P < 0.001). Conclusions The results of this analysis confirm the results from earlier time points which demonstrate the increased rate of HBsAg loss in patients treated with a finite course of PEG-IFN plus TDF compared with the rates in patients receiving either monotherapy.